Similarly, immunostainings of the tumors against antibodies for CD31 (Supplementary Figure S7H,I), VEGF (Supplementary Figure S7J,K), and OCCLUDIN (Supplementary Figure S7L,M) showed that Prox1 reduced all three markers, indicating a decrease in angiogenesis as well as in the EMT capacity of the breast cancer tumors. This evidence concerns the gene PECAM1 and breast carcinoma.